Our current technical analysis of Cytodyn (OTC:CYDY)


USD 0.42  0.01  2.33%   

As many millenniums are trying to avoid healthcare space, it makes sense to break down Cytodyn a little further and try to understand its current market patterns. For some short-term oriented investors Cytodyn may be the right move right now, Let's take a closer look. Cytodyn hyperactively responds to market trends. A lot of the movements of the company otc stock price movements has been a reflection of what is happening in the market overall. Strong fundamental indicators of the company may suggest signs of short-term price drift for investors. The otc stock experiences above-average trading activities.
Published over a month ago
View all stories for Cytodyn | View All Stories
Cytodyn's average rating is Hold from 1 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on Cytodyn market sentiment investors' perception of the future value of Cytodyn. Let us look at a few aspects of Cytodyn technical analysis.
Using predictive technical analysis, we will analyze different prices and returns patterns and diagnose historical swings to determine the real value of Cytodyn. In general, we focus on analyzing Cytodyn stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Cytodyn's daily price indicators and compare them against related drivers such as momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of Cytodyn's intrinsic value. In addition to deriving basic predictive indicators for Cytodyn, we also check how macroeconomic factors affect Cytodyn price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Cytodyn's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Cytodyn in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Cytodyn. Your research has to be compared to or analyzed against Cytodyn's peers to derive any actionable benefits. When done correctly, Cytodyn's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Cytodyn.

Watch out for price decline

Please consider monitoring Cytodyn on a daily basis if you are holding a position in it. Cytodyn is trading at a penny-stock level, and the possibility of delisting is much higher compared to other otcs. However, just because the otc stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as Cytodyn stock to be traded above the $1 level to remain listed. If Cytodyn otc stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.

How important is Cytodyn's Liquidity

Cytodyn financial leverage refers to using borrowed capital as a funding source to finance Cytodyn ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Cytodyn financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Cytodyn's total debt and its cash.

How does Cytodyn utilize its cash?

To perform a cash flow analysis of Cytodyn, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Cytodyn is receiving and how much cash it distributes out in a given period. The Cytodyn cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.

Acquisition by Arman Arvin Cyrus of 1575557 shares of Cytodyn subject to Rule 16b-3

Legal trades by Cytodyn insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Cytodyn insider trading alert for grant of non-qualified stock option (right to buy) by Arman Arvin Cyrus, President, on 22nd of September 2022. This event was filed by Cytodyn Inc with SEC on 2022-09-22. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Closer look at Cytodyn Variance

Cytodyn has current Variance of 98.03. Variance is another measure of security risk that shows the amount of dispersion of equity returns around their mean value. Variance is calculated as the average squared deviations from the mean. Evaluating a set of investment alternatives one can use variance to help determine the volatility when purchasing a specific security. Similar to Standard Deviation, the variance is a measure of how far a set of numbers is spread out around its mean.

Variance is also a measure of stock volatility and can help determine the risk an investor might take on when purchasing a specific security. A relatively big variance indicates that the daily prices or returns are far from the mean and a small variance indicates that they are located around the mean.

SUM = Summation notation
RET DEV = Actual returns deviation over selected period
N = Number of points for the period
Let's now compare Cytodyn Variance to its closest peers:

Breaking up Cytodyn current price slide

Potential upside is down to 21.21. It may suggest a possible volatility slide. Cytodyn is displaying above-average volatility over the selected time horizon. Investors should scrutinize Cytodyn independently to ensure intended market timing strategies are aligned with expectations about Cytodyn volatility. Cytodyn is a potential penny stock. Although Cytodyn may be in fact a good instrument to invest, many penny otc stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Cytodyn. We encourage investors to look for the signals such us email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Cytodyn instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of an artificial hype usually unable to maintain its increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.

Our Takeaway on Cytodyn Investment

While some companies in the biotechnology industry are either recovering or due for a correction, Cytodyn may not be performing as strong as the other in terms of long-term growth potentials. To conclude, as of the 13th of August 2022, our research shows that Cytodyn is a rather out of control investment opportunity with a below average odds of financial turmoil in the next two years. From a slightly different view, the entity currently appears to be fairly valued. Our current 90 days 'Buy-Sell' recommendation on the company is Cautious Hold.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Cytodyn. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com